REFERENCES
- Banks BC. Monitoring aminoglycosides, J Antimicrob Chemother. 1990; 26: 145-148.
- Reeves DS. Therapeutic drug monitoring of aminoglyco-side antibiotics, Infection, 1980; 8: S313–320.
- Edason RS, Terrel CL. The aminoglycosides, Mayo Clin Proc, 1991; 66: 1158-1164.
- Phillips I. Good antimicrobial prescribing - aminoglyco-sides, Lancet, 1982; II: 311-315.
- Sarubbi FA, Hull JH. Amikacin serum concentrations: prediction of levels and dosage guidelines, Ann Intern Med, 1978; 89: 612–618.
- Editorial. Aminoglycoside toxicity, Lancet, 1986; II: 670-671.
- Cronin RE. Aminoglycosides nephrotoxicity: pathogenesis and prevention, Clin Nephrol, 1979; 11: 251–256.
- Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak con-centration to minimal inhibitory concentration. J Infect Dis, 1987; 1: 93–99.
- Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma level with therapeutic outcome in gram-negative bacteremia. Am J Med, 1984; 77: 657–662.
- Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis, 1984; 149: 443–488.
- Bodenham A, Shelly MP, Park GR. The altered phar-macokinetics and pharmacodynamics of drugs commonly used in critically ill patients, Drugs, 1988; 14: 347–373.
- Mann HJ, Fuhs DH, Awang R, Ndemo FA, Cerra FA. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm, 1987; 6: 148–163.
- N000ne PT, Parsons MC, Pattison JR, Slack RS, Garfield-Davies D, Hughes K. Experience in monitoring gen-tamicin therapy during treatment of serious gram-negative sepsis. Br J Med, 1974; 1: 477–481.
- Mitchell MD, Wilson J, Dodek P, Russel J. Volume dis-tribution in patients with Gram-negative sepsis in the ICU, Anesthesiology, 1987; 67: A126.
- Sumner WR, Michael JR, Lipsky JJ. Initial aminoglyco-sides levels in the critically ill. Crit Care Med, 1983; 11: 948–50.
- El Saghir NS, Hall AD, Santhosh-Kummar CR, Zeitany RG. Infectious complications during therapy of acute leukemia in Saudi Arabia. J Hosp Infect, 1989; 14: 403–418.
- Davis RL, Lehmann D, Stidley CA, Neidhart J. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob Agents Chemother, 1991; 35: 944–947.
- Moore RD, Smith CR, Lietman PS. The association of aminogylcoside plasma levels with mortality in patients with gram negative bacteremia. J Infect Dis, 1984; 149: 443–448.
- Zeitany RG, El Saghir NS, Santhosh-Kummar CR, Sigmon MA. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother, 1990; 35,5: 702–708.
- Hallworth BJ. Audit of therapeutic drugs monitoring. Ann Clin Biochem, 1988; 25: 121–128.
- Kimelblatt BJ, Bradbury K, Chodoff L, et al. Cost ben-efit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm, 1986; 43: 1205–1209.
- Hallworth MJ. Practical therapeutic drug monitoring: aminoglycoside antibiotics. Lab Medica, 1990; 17–19.